11月5日，诺和诺德第三季度净销售额为749.76亿丹麦克朗，同比增长5%，市场预估766.8亿丹麦克朗。
净利润为200.06亿丹麦克朗，同比减少27%。
第三季度GLP-1药物销售额367.4亿丹麦克朗，预估372.7亿丹麦克朗。
第三季度Wegovy销售额203.5亿丹麦克朗，预估209.4亿丹麦克朗。
公司预计2025年资本支出为600亿丹麦克朗，此前预计约为650亿丹麦克朗。
财报发布后，诺和诺德美股夜盘跌近3%。
11月5日，诺和诺德第三季度净销售额为749.76亿丹麦克朗，同比增长5%，市场预估766.8亿丹麦克朗。
净利润为200.06亿丹麦克朗，同比减少27%。
第三季度GLP-1药物销售额367.4亿丹麦克朗，预估372.7亿丹麦克朗。
第三季度Wegovy销售额203.5亿丹麦克朗，预估209.4亿丹麦克朗。
公司预计2025年资本支出为600亿丹麦克朗，此前预计约为650亿丹麦克朗。
财报发布后，诺和诺德美股夜盘跌近3%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
